

European Medicines Agency Evaluation of Medicines for Human Use

> London, 12 March 2009 Doc. Ref.: EMEA/HMPC/664610/2008

OVERVIEW OF COMMENTS RECEIVED ON 'COMMUNITY HERBAL MONOGRAPH ON *CENTAURIUM ERYTHRAEA* RAFN, HERBA' (EMEA/HMPC/105536/2008)

This document was valid from 12 March 2009 until 24 November 2015.

<u>Table 1</u>: Organisations providing comments on the draft 'Community herbal monograph on *Centaurium erythraea* Rafn, herba' as released for consultation on 17 July 2008 until 15 November 2008.

	Organisation	
1.	PhytoLab GmbH & Co. KG, Germany	

Table 2: Discussion of comments

no. Traditional use Not endorsed. 4.2. Posology According to the HMPC monograph (draft) for Centaurium erythraea Not endorsed. and method of admini- The use in children and adolescents under 18 years of age is not The safety has not been demonstrated in children and adolescents under 18 years, because no studies or exposure data have been submitted.	4. CLINICAI	L PARTICULARS	
Posology and method of admini- stration Traditional lise Not endorsed. According to the HMPC monograph (draft) for Centaurium erythraen "The use in children and adolescents under 18 years of age is not recommended because of lack of data." The safety has not been demonstrated in children and adolescents und 18 years, because no studies or exposure data have been submitted. Although there are no data on the use of centaury in this age group, this restriction is regarded to be not adequate and should be modified because of the following reasons: The safety has not been demonstrated in children and adolescents und 18 years, because no studies or exposure data have been submitted. 1. There are no data pointing to any risks associated with the use of the drug in children or adolescents. 1. There are no data pointing to any risks associated with the use of the drug to children is the "proportion of adult dose according to age or body weight, in ethanol-free dosage forms". Two traditional herbal combination products, containing among others aqueous-ethanolic extracts from centaury, are on the market in Germany (Montana Haustropfen N, Canephron® N Tropfen). Both products are indicated for the use in adults and adolescents over 12 years of age. Therefore we suggest the following modifications of the monograph: 4.2 Posology and method of administration: "Adolescents over 12 years of age: Proportion of adult dose according to age or body weight." "The use is not recommended in children under 12 years of age (see	Paragraph no.	Comment and Rationale	Assessor's Comment
	4.2. Posology and method of admini- stration	 According to the HMPC monograph (draft) for Centaurium erythraea "The use in children and adolescents under 18 years of age is not recommended because of lack of data." Although there are no data on the use of centaury in this age group, this restriction is regarded to be not adequate and should be modified because of the following reasons: There are no data pointing to any risks associated with the use of the drug in children or adolescents. According to the ESCOP monograph on Centaurii herba the dose recommendation for children is the "proportion of adult dose according to age or body weight, in ethanol-free dosage forms". Two traditional herbal combination products, containing among others aqueous-ethanolic extracts from centaury, are on the market in Germany (Montana Haustropfen N, Canephron® N Tropfen). Both products are indicated for the use in adults and adolescents over 12 years of age. Therefore we suggest the following modifications of the monograph: 4.2 Posology and method of administration: "Adolescents over 12 years of age: Proportion of adult dose according to age or body weight." 	The safety has not been demonstrated in children and adolescents under

4.4. Special warnings	Traditional use	Not endorsed.
and	4.4 Special warnings and precautions for use:	The safety has not been demonstrated in children and adolescents under
precautions for use	"The use in children under 12 years of age is not recommended because of lack of data."	18 years, because no studies or exposure data have been submitted.
	© EMEA 2009	3/3